BioNTech (BNTX) Stock Overview
A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BNTX from our risk checks.
BNTX Community Fair Values
Create NarrativeSee what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.
BioNTech SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$111.00 |
| 52 Week High | US$131.49 |
| 52 Week Low | US$79.88 |
| Beta | 1.24 |
| 1 Month Change | -1.67% |
| 3 Month Change | 20.54% |
| 1 Year Change | 33.99% |
| 3 Year Change | -30.79% |
| 5 Year Change | 63.52% |
| Change since IPO | 679.49% |
Recent News & Updates
Recent updates
The BioNTech SE (NASDAQ:BNTX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 08
BioNTech: More Uncertainty Emerges
Jul 14Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?
Jul 01BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
Mar 17Analysts Just Slashed Their BioNTech SE (NASDAQ:BNTX) EPS Numbers
Mar 16
Advancing Oncology Pipeline May Drive Future Growth Amid Near-Term Earnings Pressure
Promising oncology assets, improved R&D efficiencies, and strategic partnerships drive potential long-term revenue growth and shareholder value for BioNTech.BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
Jan 23BioNTech SE (NASDAQ:BNTX) Investors Are Less Pessimistic Than Expected
Jan 15BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Nov 06BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates
Nov 06BioNTech's Oncology Gamble: High Stakes, Big Potential
Oct 21BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23Shareholder Returns
| BNTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.06% | -3.4% | 0.7% |
| 1Y | 34.0% | -7.9% | 19.4% |
Return vs Industry: BNTX exceeded the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: BNTX exceeded the US Market which returned 19.4% over the past year.
Price Volatility
| BNTX volatility | |
|---|---|
| BNTX Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BNTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BNTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 6,772 | Ugur Sahin | www.biontech.de |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.
BioNTech SE Fundamentals Summary
| BNTX fundamental statistics | |
|---|---|
| Market cap | US$26.27b |
| Earnings (TTM) | -US$402.80m |
| Revenue (TTM) | US$3.36b |
Is BNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNTX income statement (TTM) | |
|---|---|
| Revenue | €2.88b |
| Cost of Revenue | €582.60m |
| Gross Profit | €2.30b |
| Other Expenses | €2.64b |
| Earnings | -€344.80m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 03, 2025
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 79.76% |
| Net Profit Margin | -11.98% |
| Debt/Equity Ratio | 0.2% |
How did BNTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/12 21:47 |
| End of Day Share Price | 2025/08/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNTech SE is covered by 36 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Harry Gillis | Berenberg |
| Zhiqiang Shu | Berenberg |